Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 20 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 1029 Carboplatin 966 Paclitaxel 941 Gemcitabine 798 Cisplatin 754 Docetaxel 697 Bevacizumab 638 Nivolumab 519 Pemetrexed 507 Capecitabine 475 Cyclophosphamide 468 Fluorouracil 424 Dexamethasone 409 Rituximab 391 Oxaliplatin 351 Injections 344 Trastuzumab 313 atezolizumab 311 Cetuximab 291 Leucovorin 288 Irinotecan 269 130-nm albumin-bound paclitaxel 255 Prednisone 250 Ipilimumab 244 Doxorubicin 241 Lenalidomide 231 Fulvestrant 226 fludarabine 215 durvalumab 211 Erlotinib Hydrochloride 196

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Registries × Clear all

NCT02454595 2017-09-05

Registry to Measure the Impact of Adding Genomic Testing

Myriad Genetic Laboratories, Inc.

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡